Mark Tidswell to Prospective Studies
This is a "connection" page, showing publications Mark Tidswell has written about Prospective Studies.
Connection Strength
0.099
-
Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med. 2010 Jan; 38(1):72-83.
Score: 0.052
-
Lanspa MJ, Gong MN, Schoenfeld DA, Lee KT, Grissom CK, Hou PC, Serpa-Neto A, Brown SM, Iwashyna TJ, Yealy DM, Hough CL, Brower RG, Calfee CS, Hyzy RC, Matthay MA, Miller RR, Steingrub JS, Thompson BT, Miller CD, Clemmer TP, Hendey GW, Huang DT, Mathews KS, Qadir N, Tidswell M. Prospective Assessment of the Feasibility of a Trial of Low-Tidal Volume Ventilation for Patients with Acute Respiratory Failure. Ann Am Thorac Soc. 2019 03; 16(3):356-362.
Score: 0.025
-
Brown SM, Duggal A, Hou PC, Tidswell M, Khan A, Exline M, Park PK, Schoenfeld DA, Liu M, Grissom CK, Moss M, Rice TW, Hough CL, Rivers E, Thompson BT, Brower RG. Nonlinear Imputation of PaO2/FIO2 From SpO2/FIO2 Among Mechanically Ventilated Patients in the ICU: A Prospective, Observational Study. Crit Care Med. 2017 Aug; 45(8):1317-1324.
Score: 0.022